MORGAN STANLEY: “While a pre-election result is possible, we see early-to-mid November as our base case for [Phase 3 vaccine] data. .. Pfizer/BioNTech and Moderna appear slightly ahead of AstraZeneca.”

$PFE $MRNA https://t.co/a6kNWVmTJd